Actinium Pharmaceuticals (ATNM) Competitors

ALT5 Sigma (NASDAQ:ALTS) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Which has preferable earnings & valuation, ALTS or ATNM?

ALT5 Sigma has higher revenue and earnings than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$12.53M	12.43	-$6.24M	N/A	N/A
Actinium Pharmaceuticals	N/A	N/A	-$48.82M	-$1.31	-1.26

Do institutionals and insiders hold more shares of ALTS or ATNM?

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media favor ALTS or ATNM?

In the previous week, ALT5 Sigma had 14 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 17 mentions for ALT5 Sigma and 3 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.00 beat ALT5 Sigma's score of 0.76 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ALT5 Sigma	Positive
Actinium Pharmaceuticals	Positive

Do analysts recommend ALTS or ATNM?

Actinium Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 172.73%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, ALTS or ATNM?

ALT5 Sigma has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500.

Is ALTS or ATNM more profitable?

Actinium Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Actinium Pharmaceuticals' return on equity of -100.85% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-74.89%	-179.27%	-16.28%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks.